PCK3145 is an anti-metastatic synthetic peptide against prostate cancer. The objective of the study is to develop and validate novel and sensitive methods for the determination of PCK3145 and Pegylated PCK3145 in mouse plasma. An LC-MS/MS method was developed and validated for the determination of PCK3145 giving high sensitivity and linearity in the range of 0.125-4.0 μg/mL. PCK3145 characterised by short half-life, therefore, it was conjugated with the poly ethylene glycol (PEG). However, LC-MS/MS has been more difficult to apply for the quantitative analysis of PEGylated peptides due to the large size. A UHPLC-UV method was developed and validated for the determination of PEG-PCK3145, with linearity of 0.05-2.0 mg/mL. In order to further improve the sensitivity for the detection of PEG-PCK3145, an indirect ELISA method was used. It was found that this method was capable of detecting PCK3145 through the quantification of PEG with excellent sensitivity found at 0.132 ng/mL. The in vitro proteolytic stability of PCK3145 and PEG-PCK3145 in mouse plasma and whole blood was studied by LC-MS/MS and UHPLC, respectively. The LC-MS/MS and ELISA methods can be applied for monitoring levels of PCK3145 in mouse plasma for in vivo pharmacokinetic and bioavailability animal studies.

01 Jul 2017·Journal of Nanoscience and Nanotechnology

Preparation and Physicochemical Characterization of Polyelectrolyte Complexes Incorporating Antitumor Peptide

Author: Demetzos, Costas ; Sivolapenko, Gregory ; Pippa, Natassa ; Pispas, Stergios ; Mountrichas, Gregory

In this work, tigapotide (PCK3145) was incorporated into novel block copolymer polyelectrolyte nanocarriers in order to maximize the advantages of the delivery process and possibly its biological properties. PCK3145 was incorporated into complexes with the block polyelectrolyte poly(vinyl benzyl trimethylammonium chloride)-b-poly(oligo(ethylene glycol) methyl ether methacrylate) (PVBTMAC-POEGMA). Light scattering techniques (dynamic, static and electrophoretic) are used in order to examine the size, the size distribution, the morphology and the z-potential of the nanocarriers incorporating PCK3145 in different aqueous media. The concentration of PVBTMAC-POEGMA is kept constant throughout the series of aqueous solutions of different ionic strength investigated. The values of the scattering intensity, I90, which is proportional to the mass of the species in solution, increase gradually as a function of CPCK3145 providing proof of the occurring complexation. It was shown that the structure and solution behavior of the formed complexes depend on the ratio of the two components, as well as on the pH and the ionic strength of the solution. The physicochemical characteristics of the complexes, as a function of PCK concentration, remained unaffected at higher ionic strength (0.154 M). This investigation provides interesting and useful new insights into the interaction mechanism between oppositely charged block polyelectrolytes and therapeutic peptides.

01 Sep 2016·Biomedical ChromatographyQ4 · MEDICINE

Development and validation of a UHPLC‐UV method for the determination of a prostate secretory protein 94‐derived synthetic peptide (PCK3145) in human plasma and assessment of its stability in human plasma

Q4 · MEDICINE

Article

Author: Katsila, Theodora ; Leontari, Iliana ; Sivolapenko, Gregory ; Danika, Charikleia ; El Mubarak, Mohamed A.

AbstractPCK3145 is a synthetic peptide, derived from the Prostate Secreted Protein 94 (PSP94), with promising in vitro and animal in vivo results in prostate cancer. The aim of the present study was to develop and validate a fast and robust ultra‐high‐performance liquid chromatography with ultraviolet detection for the determination of PCK3145 in human plasma which would be suitable for the assessment of PCK3145 stability to proteolytic degradation. Following protein precipitation, chromatographic separation was carried out on an Aeris Peptide C18 column with mobile phase consisting of acetonitrile–water at a flow‐rate of 0.50 mL/min. The calibration curve was linear over the range 0.50–20.00 μg/mL. Intra‐ and inter‐day percentage relative standard deviation and relative error were ≤10%. The limit of detection and the lower limit of quantification were 0.15 and 0.50 μg/mL, respectively. Recovery of PCK3145 from human plasma was ≥96%. The peptide presented high stability in whole blood and in human plasma (>98% intact peptide after 24 h incubation at 37°C in human plasma), which represents a distinctive advantage in the therapeutic use of the compound. This is the first validated UHPLC method for the determination of PCK3145 reported, and it was successfully applied in the study of the proteolytic stability of PCK3145 in human plasma ex vivo. Copyright © 2016 John Wiley & Sons, Ltd.

100 Deals associated with Tigapotide Triflutate

External Link

KEGG	Wiki	ATC	Drug Bank
D06658	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	-	Ambrilia Biopharma, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis